GlassScriptPhysician profile
Ashley Chapman
NPI 1467741108
$1,702.14
in general payments reported to CMS, 2019-2025
24 companies · $568 in 2025
The $568 reported for 2025 was more than what 79% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $41.15 · 2023: $293 · 2024: $524 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,305 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,305.12 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $202.43 | 2023-2025 | Biktarvy, Veklury, Yeztugo |
| Viiv Healthcare Company | $172.03 | 2024-2025 | Dovato, Cabenuva, Rukobia |
| Glaxosmithkline, LLC. | $151.08 | 2021-2024 | Benlysta |
| Astellas Pharma US INC | $138.46 | 2024-2025 | Cresemba, Veozah |
| Merck Sharp & Dohme LLC | $131.92 | 2022-2025 | Pifeltro, Zerbaxa, Capvaxive |
| Apellis Pharmaceuticals, INC. | $119.05 | 2023 | |
| Incyte Corporation | $116.90 | 2021 | |
| Insmed, INC. | $89.63 | 2023-2025 | Arikayce |
| G1 Therapeutics, INC. | $71.86 | 2023 | Cosela |
| Paratek Pharmaceuticals, INC. | $58.30 | 2024-2025 | Nuzyra |
| Shionogi INC | $56.46 | 2024-2025 | Fetroja |
| Theratechnologies INC. | $55.14 | 2024-2025 | Trogarzo, Egrifta |
| La Jolla Pharmaceutical Company | $46.23 | 2024-2025 | Zevtera, Xacduro |
| Melinta Therapeutics, LLC | $45.48 | 2024-2025 | Rezzayo, Kimyrsa |
| Aimmune Therapeutics, INC. | $41.25 | 2024-2025 | Vowst |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $30.35 | 2023-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $26.67 | 2024 | Rexulti |
| Abbvie INC. | $25.99 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.43 | 2021 | |
| Lemaitre Vascular, INC. | $21.27 | 2023 | Anastoclip Gc 8cm (Medium) |
| Ferring Pharmaceuticals INC. | $20.81 | 2024 | Rebyota |
| Alkermes, INC. | $20.51 | 2022 | |
| Dynavax Technologies Corporation | $19.38 | 2024 | Heplisav-B |
| Bioxcel Therapeutics, INC. | $17.51 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.